Chinese biopharmaceutical company Mabwell (SH:688062) announced on Tuesday that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumours will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2025.

As of 15 September 2025, 74 patients with advanced solid tumour were enrolled and treated with 7MW3711 in the phase I/II study. Among 54 patients treated at 4.0 mg/kg or above and reaching tumour assessment, 19 partial responses or complete responses were observed. Seven patients with oesophageal cancer were enrolled at 4.0 mg/kg or above and achieved an objective response rate (ORR) of 42.9% and a disease control rate (DCR) of 100%. Among lung cancer patients treated at the 4.0 mg/kg Q2W and reaching tumour assessment, the ORR for small cell lung cancer (SCLC) and squamous non-small cell lung cancer (Sq-NSCLC) were 50.0% and 38.5% respectively, with DCR of 90.0% and 92.3% respectively.

No dose-limiting toxicities were observed in the dose escalation phase, and the maximum tolerated dose has not yet been reached.

Mabwell says that the study results suggest encouraging efficacy of 7MW3711 in advanced solid tumours, especially in oesophageal and lung cancer.